ABL1 and Parkinson disease: Concerning the effects of NAC in preclinical PD models, oxidative stressing states and toxic-induced α-synuclein conditions result in c-Abl activation, which is reversed by NAC administration, improving dopaminergic neuronal survival and decreasing motor symptoms [249].